Press Release on unaudited results for Q1FY27.

July 26, 2026 BSE Limited National Stock Exchange of India Limited Department of Corporate Services Listing Department, Exchange Plaza, Floor 25, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Kala Ghoda, Fort Mumbai – 400 051 Mumbai 400 001 Company Symbol: NEOGEN Scrip Code No: 542665 Debt Segment Code: 977028 Sub.: Press Release on the Unaudited Financial Results of the Company for the quarter ended June 30, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/ Madam, With reference to the captioned subject, please find enclosed herewith the Press Release on the unaudited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2026. The Press Release is also being uploaded on the Company’s website at https://neogenchem.com/financial-performance/. Kindly take the same on your record. Thanking you, For Neogen Chemicals Limited Unnati Kanani Company Secretary and Compliance Officer Mem. No. A35131 Encl.: As above Registered Office: 1002, Dev Corpora, Cadbury Junction, E: sales@neogenchem.com T: +91 22 2549 7300 Eastern Express Highway, Thane (W) 400 601, India. W: www.neogenchem.com F: +91 22 2549 7399 CIN No. L24200MH1989PLC050919 Q1 FY27 PRESS RELEASE July 26, 2026 Neogen Chemicals reports strong financial performance  Revenue at INR 250 crore, higher by 34% Y-o-Y  PAT at INR 17 crore, an increase of 67% Y-o-Y Neogen Chemicals Limited (Neogen) reported robust financial performance for the first quarter ended 30th June, 2026. In Q1 FY27 (consolidated), revenues stood at INR 250 crore, higher by 34% Y-o-Y. Strong growth was recorded despite the temporary Dahej plant shut down, driven by efficient management of toll manufacturing sites. Revenue expansion was anchored by higher volumes for key product lines. Organolithium Portfolio delivered robust gains driven by enhanced plant throughput. Neogen Ionics (NIL): Q1 FY27 revenue reached INR 19 crore (vs. INR 5 crore in Q1 FY26). EBITDA for Q1 FY27 (consolidated) stood at INR 48 crore, higher by 53% Y-o-Y. Robust EBITDA performance despite ongoing global headwinds. Cost pass-throughs were initiated for RM and input costs (freight, packaging, utilities, etc.) to protect operating margins. Performance was bolstered by favorable product mix, achieving highest-ever quarterly revenues in both Organolithium and Battery Chemicals, alongside strong volume growth in Inorganic Chemicals. This was achieved despite headwinds from higher costs, including temporary expenses related to the Dahej plant rebuild, toll manufacturing, expansion overheads at NIL, and geopolitical freight spikes. Neogen’s profit after tax for Q1 FY27 (consolidated) stood at INR 17 crore, higher by 67% Y-o-Y. PAT trajectory reflected strong underlying operating trends, partly moderated by higher finance costs (up 64% Y-o-Y). Increased interest burden was led by higher debt drawdown to fund ongoing CAPEX, increased working capital intensity driven by geopolitical supply chain inflation and delay in insurance receipts. Consolidated Earnings Per Share (EPS) for Q1 FY27 stood at INR 6.29 per share (not annualized). Performance at a Glance INR crore (Consolidated) Q1 FY27 YoY Growth Revenues 250 34% Gross Profit 117 37% EBITDA 48 53% PAT 17 67% Note: Growth for Q1 FY27 is compared to Q1 FY26. Page | 1 Press Release Commenting on the Q1 FY27 performance, Dr. Harin Kanani, Managing Director, Neogen Chemicals said: “We have delivered robust performance in Q1 FY27, marking a strong start to the new financial year. This performance was driven by volume gains across our core business lines led by sustained customer off-take and the highest revenue ever recorded in our Organolithium portfolio, alongside a stellar start at Neogen Ionics, which generated over 50% of its entire prior-year revenue in Q1 FY27 alone. Despite global supply chain pressures, elevated inputs costs and plant transition activities at Dahej, our underlying business fundamentals remain sound. As our replacement Dahej plant scales up, we are well-positioned to leverage our expanded capacities and drive sustainable growth. Our battery materials project remains firmly on track with projected timelines. Backed by successful customer validations, international site audits, and key client approvals, Neogen Ionics stands at a pivotal junction, uniquely positioned as a preferred partner for domestic and global cell manufacturers. This position is further strengthened by favorable Government support and policy actions, alongside production ramp-up by PLI ACC battery manufacturers and the allocation of the 10 GWh re-bidding tranche. More importantly, the Government’s intention to incentivize battery component manufacturers through a proposed PLI scheme will accelerate supply chain localization. Through the localization of advanced battery chemistry, we will actively support India’s mission to build a self-reliant domestic ecosystem for EV and energy storage applications, while servicing global non-FEOC demand. Moving forward, FY27 will be a defining year of execution for Neogen Chemicals, as we commission and scale up our battery materials project to emerge as a critical player in the battery chemicals ecosystem. Concurrently, with our replacement Dahej facility nearing operational readiness, our core base business is set to resume its normalized growth trajectory this year. Reaffirming our previously shared guidance, we remain focused on executing our strategic CAPEX roadmap and unlocking operating leverage to deliver sustainable, long-term growth and value creation for shareholders.”. Key Updates – Q1 FY27 (Neogen Chemicals)  Update on Dahej Fire Incident o Cumulative recoveries stand at INR 164 crore to date, comprising INR 155 crore in on- account insurance claims (including a recent tranche of INR 15 crore in July 2026) and INR 9 crore from salvage realization and has incurred further incidental charges of INR 1 Crore which is also claimed as per insurance policy upto June 30, 2026. Hence, the net claim receivable as on date stands at INR 186 crore on a consolidated basis. o Reconstruction of the Dahej plant is complete, with trial runs underway; commercial production to begin soon  Board Approval for Fund Raise o The Board has approved raising up to INR 600 Crore (in INR or foreign currency) through issue of eligible securities, by way of a Qualified Institutional Placement (QIP), subject to necessary shareholder and statutory approval Page | 2 Press Release UPDATE ON EXPANSION INITIATIVES Details of expansion projects announced: Current project updates: Battery Chemicals Business  200 MTPA commissioned; first approval material shipped to the customers Capacity of 1,500 MTPA for manufacturing Lithium Electrolyte Salts and Additives  For remaining 1,300 MTPA, trial production ongoing  1,000 MT to be commissioned by H2 FY27 New Capacity of 1,000 MTPA for manufacturing  500 MT additional intermediate to be Lithium Electrolyte Salts and Additives commissioned in H2 FY27 Plant for manufacturing 2,000 MT of Electrolyte at  2,000 MT fully commissioned Dahej facility Update on Battery Chemicals (Neogen Ionics) Execution Roadmap & CAPEX  Total estimated project cost for Neogen Ionics’ Dahej Phase 1 and Pakhajan Phase 2 Battery Materials projects stands at INR 1,795 crore (INR 218 crore incurred in Q1 FY27; cumulative INR 1,298 crore to date) o Dahej Phase 1 project cost stands at INR 428 crore with target completion by February 2027, while Pakhajan Phase 2 is budgeted at INR 1,367 crore with completion expected by March 2027 o Project scope and specifications reflect design optimizations following the transition to advanced Japanese technology, alongside enhanced localization of critical sub- components to reduce import dependence and boost long-term operational reliability o Both projects continue to receive strong strategic backing through promoter equ [Showing first 8,000 characters — download PDF for full document]